Ozurdex 700 _g per implan Intravitreal implant in applicator
PDF Leaflet Revision Date: 12 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of visual impairment due to DME, macular oedema from BRVO/CRVO, and non-infectious uveitis.
Dosage (summary)
One implant administered intra-vitreally; retreatment after ~6 months if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to potential risks.
Key Drug Interactions
- CYP450 3A4 inhibitors may increase corticosteroid effects
- Caution with anticoagulants and anti-platelets
Contraindications
- Hypersensitivity to dexamethasone
- Active ocular infections
- Uncontrolled glaucoma
- Aphakic eyes with posterior capsule rupture
Common side effects
- Increased intraocular pressure
- Cataract
- Conjunctival haemorrhage
- Visual disturbance
Counselling Points
- Monitor for signs of infection
- Report visual changes immediately
- Avoid driving until vision stabilizes
Serious warnings
- Risk of endophthalmitis
- Increased intraocular pressure
- Potential for implant migration
Important Disclaimer
The Ozurdex 700 _g per implan Intravitreal implant in applicator professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
